Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ESMO 2022
Pharma
As Keytruda's shine wanes, can Merck build a 2nd blockbuster?
As the patent expiration for Keytruda nears, Merck has a multipronged approach to extend the life of the drug and find its next blockbuster.
Max Bayer
Sep 29, 2022 3:35pm
'The Top Line': Merck's poor ESMO show, monkeypox test EUAs
Sep 16, 2022 6:00am
ESMO: Roche spots untouched 1L NSCLC market for solo Tecentriq
Sep 12, 2022 10:30am
ESMO: Exelixis faces uphill battle with kidney cancer triplet
Sep 12, 2022 10:30am
UPDATED: Amgen's latest KRAS data leave room for competition
Sep 11, 2022 6:05pm
ESMO: Keytruda's failed head and neck cancer data show hope
Sep 11, 2022 10:30am
